Physician profile
Gerald Katz
NPI 1306868450
$3,167.96
in general payments reported to CMS, 2019-2025
27 companies · $626 in 2025
The $626 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $191 · 2021: $278 · 2022: $422 · 2023: $691 · 2024: $400 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.88 |
| Education | $199.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.84 | 2019-2023 | |
| Astellas Pharma US INC | $394.47 | 2023-2025 | Veozah |
| Pfizer INC. | $324.56 | 2019-2025 | |
| Organon LLC | $216.17 | 2021-2025 | Nexplanon |
| Biogen, INC. | $192.19 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $161.19 | 2022-2025 | |
| Exeltis, USA INC. | $121.86 | 2024-2025 | Slynd |
| Exact Sciences Corporation | $114.59 | 2023-2025 | Cologuard Collection Kit |
| Minerva Surgical, INC | $99.05 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $89.28 | 2019-2021 | |
| Agile Therapeutics, INC. | $88.30 | 2022-2024 | Twirla |
| Myovant Sciences INC. | $83.52 | 2022 | |
| Coopersurgical, INC. | $75.81 | 2020-2024 | Paragard T 380a |
| Therapeuticsmd, INC. | $67.21 | 2019-2021 | |
| Millicent US INC | $63.13 | 2024-2025 | Intrarosa, Femring, Femlyv |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $62.72 | 2019-2023 | |
| Avion Pharmaceuticals | $58.99 | 2021-2022 | |
| Lupin INC. | $45.32 | 2019-2020 | |
| Hologic Sales and Service, LLC | $44.40 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $42.30 | 2019-2020 | |
| Daiichi Sankyo INC. | $34.58 | 2019 | |
| Vertical Pharmaceuticals, LLC | $21.66 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $21.65 | 2023 | Exparel |
| Sumitomo Pharma America, INC. | $19.73 | 2023 | Myfembree |
| Evofem Biosciences, INC. | $17.61 | 2025 | Solosec, Phexx, Phexxi |
| Allergan, INC. | $15.78 | 2019 | |
| Mimedx Group, INC. | $14.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.